Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by allinenergy2on Sep 21, 2015 3:10pm

166 Views

Post# 24122741

RE:RE:Here comes 20!!!

Did I miss somthing? What exactly does AEZ have to do with ATE?

Now if you want something relevant, look at GUD, whose CEO used to be a Director of ATE and still has a very good relationship with.

If Knight Therapeutics comes into the picture after validation results or later, then that would be a catalyst for share price appreciation in my opinion. Good luck to all here.

KeystoneXLlobby wrote: jackstrongcow...lets not start jerking each other off just yet...this is in reaction to AEZ. will get back down without any pr.

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide